Description

Product Availability: In Stock (FedEx delivery within 2 business days).

Ordering: To place an order please use Add to Cart button (account not required).

NANOPARTICLE-based In Vivo Transfection Kit
Small RNA (siRNA, microRNA, mRNA) and plasmid DNA in vivo delivery reagent

Modes of administration:

• Systemic intravenous (i.v.) injection
• Direct intratumoral (i.t.) injection

Altogen’s NANOPARTICLE In Vivo Transfection Reagent

• Efficient delivery to the brain, heart, lung, liver, pancreas, kidney, and multiple tumor types via tail vein administration
• Functionally tested in mice (BALB/c, Nude, NOD/SCID) and Sprague Dawley rats
• Complexes are stable in serum for 16 hours. Applicable for plasmid DNA and siRNA co-injection
• Efficient siRNA and pDNA delivery via direct subcutaneous tumor injection (various tumor types)
• Minimal toxicity. No significant change in cytokines expression and other safety biomarkers were observed
• Download NANOPARTICLE-based in vivo transfection protocol: [PDF] [Word]
• Download PowerPoint presentation for NANOPARTICLE-based in vivo transfection kit: [PPT]
• Download safety data sheet: [PDF]
• UPC/GTIN/EAN: 860002089702
• Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

DATA

Brain transfection. Delivery of RNA and DNA biomolecules into the mouse brain tissue and glioblastoma brain tumor.

Figure 1. Systemic administration (i.v.) of Nanoparticle In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or scrambled sequence non-silencing siRNA control (or pDNA expression vector encoding Lamin A) and following the recommended transfection protocol. Nanoparticle conjugated RNA/DNA complexes were injected at constant pressure into the tail veins of NOD/SCID mice (orthotopic glioblastoma xenograft model developed by Altogen Labs). Following 72 hours post first injection, the brain and brain tumor tissues were homogenized and lysed in RIPA Buffer supplemented with protease inhibitor cocktail. High sensitivity BCA protein assay was used to normalize the protein concentration from each individual sample. Quantitative immunoblotting was performed to analyze for the change in Lamin A expression levels using the automated western blot system WES (Protein Simple; San Jose, CA). Images acquired with the contrast set to white −100 and black 4000 for standardization. Mice treated with scrambled non-silencing siRNA served as controls. Statistical data analysis were conducted using Compass software. Technical replicates (n=10). Biological replicates (n=5). P-value < 0.01

Figure 2. Intravenous administration of Nanoparticle In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or scrambled sequence non-silencing siRNA control (or pDNA expression vector encoding Lamin A) and following the recommended transfection protocol. Nanoparticle conjugated RNA/DNA complexes were injected at constant pressure into the tail veins of NOD/SCID mice. Following 72 hours post first injection, the spleen and kidney tissues were homogenized and lysed in RIPA Buffer supplemented with protease inhibitor cocktail. High sensitivity BCA protein assay was used to normalize the protein concentration from each individual sample. Quantitative immunoblotting was performed to analyze for the change in expression of Lamin A using the automated western blot WES system. Images acquired with the contrast set to white −100 and black 4000 for standardization. Statistical data analysis were conducted using Compass software. Technical replicates (n=10). Biological replicates (n=5). P-value < 0.01

Figure 3. Intravenous administration of Nanoparticle In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or scrambled sequence non-silencing siRNA control (or pDNA expression vector encoding Lamin A) and following the recommended transfection protocol. Nanoparticle conjugated RNA/DNA complexes were injected at constant pressure into the tail veins of NOD/SCID mice. Following 72 hours post first injection, the lung and heart tissues were homogenized and lysed in RIPA Buffer supplemented with protease inhibitor cocktail. High sensitivity BCA protein assay was used to normalize the protein concentration from each individual sample. Quantitative immunoblotting was performed to analyze for the change in expression of Lamin A using the automated western blot WES system. Images acquired with the contrast set to white −100 and black 4000 for standardization. Statistical data analysis were conducted using Compass software. Technical replicates (n=10). Biological replicates (n=5). P-value < 0.01

Figure 4. Intravenous administration of Nanoparticle In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or scrambled sequence non-silencing siRNA control (or pDNA expression vector encoding Lamin A) and following the recommended transfection protocol. Nanoparticle conjugated RNA/DNA complexes were injected at constant pressure into the tail veins of NOD/SCID mice. Following 72 hours post first injection, the liver and pancreas tissues were homogenized and lysed in RIPA Buffer supplemented with protease inhibitor cocktail. High sensitivity BCA protein assay was used to normalize the protein concentration from each individual sample. Quantitative immunoblotting was performed to analyze for the change in expression of Lamin A using the automated western blot WES system. Images acquired with the contrast set to white −100 and black 4000 for standardization. Statistical data analysis were conducted using Compass software. Technical replicates (n=10). Biological replicates (n=5). P-value < 0.01

Figure 5. Systemic administration (i.v.) of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after post first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

ALTOGEN® IN VIVO Transfection Kits supplied with ready-to-run transfection protocols that eliminate the need for extensive transfection optimization experiments. Read more about transfection technology at Altogen’s Transfection Resource.

Nanoparticle Transfection Reagent citation references:

• Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
• Cardiovascular Research. 2016. 110(1):30-39. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Zungu-Edmondson et al et al [PDF]
• Hypertension 2015. 65(6):1307-15. Hypoxia-independent upregulation of placental hypoxia inducible factor-1 gene expression … Iriyama T et al [PDF]
• Diabetologia. 2015 Aug; 58(8): 1949–1958. Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Zheng et al [PDF]
• J Mol Cell Cardiol. 2015 Jan; 0: 174–185. Netrin-1 Abrogates Ischemia Reperfusion-induced Cardiac Mitochondrial Dysfunction via Nitric Oxide-dependent Attenuation of NOX4 Activation and Recoupling of NOS. Siu et al [PDF]
• J Cereb Blood Flow Metab. 2017 Jul;37(7):2359-2367. Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin. Liu et al [PDF]
• Nature Medicine. 2016 22, 1131–1139. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Wang et al [PDF]

Altogen Labs Preclinical Research Services:

Altogen Labs provides GLP compliant CRO services for preclinical research, IND applications, and drug development. Biology contract research services includes over 90 in-house validated xenograft models), development of stable cell lines in just 28 days, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and many other research laboratory studies (both efficacy and safety).

Volume Options:

• 0.5 ml – 10 injections (Catalog #5030)
• 1.5 ml – 30 injections (Catalog #5031)
• 8.0 ml – 160 injections (Catalog #5032)
• 25 ml – 50 rat injections or 500 mouse injections (Catalog #5033)

AltogenBiosystems是一家开发和制造用于生命科学研究，药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化，可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外（癌细胞系）和体内（动物组织靶向试剂、癌细胞系）递送货物分子，包括质粒DNA，各种类型的RNA（mRNA，siRNA，shRNA，microRNA），蛋白质和小分子研究。 

Altogen生命科学公司致力于研发，生产和销售特定细胞系的转染试剂，用于细胞间生物分子的传递，并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。Altogen公司开发的聚合物，脂质体，纳米粒子为基础的转染技术分别针对分子生物学，组合化学，和细胞生物学而分别应用。Altogen定制服务提供符合GLP要求定制研究服务，包括代稳定的细胞系，细胞银行和冷冻保存，焦磷酸测序，克隆，RNA干扰（RNAi）和基因沉默服务，发展分析，siRNA文库筛选，并转染服务。稳定的肿瘤细胞株和原代细胞的产生，可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择，无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务，包括设计与合成的siRNA的利益，验证siRNA的沉默效率，siRNA转染条件的优化，使高效的基因沉默细胞系或原代培养细胞的靶基因。转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质（即RNA或DNA），通常是在生物实验室用来研究基因功能，基因表达的调节，生化映射，突变分析，和蛋白质的生产。科学家利用各种载体分子，这种分子，使质粒DNA（PDNA），信使RNA（mRNA），短干扰RNA（siRNA），小分子RNA（miRNA）的，并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是，无单提货的方法或转染试剂，可以适用于所有类型的细胞，细胞的细胞毒性和转染效率显着不同，取决于试剂，协议，并正在利用细胞类型。Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。纳米粒子，脂质和聚合物基ALTOGEN®在体内转染试剂，使交付功能的RNA和DNA分子在体内。PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应，并提供高效的siRNA转染的DNA，并在体内的蛋白质。由科学“杂志（2010年12月17日）：PEG脂质体在体内转染试剂盒siRNA的特色Altogen生物系统功能的特定细胞系转染试剂盒

120+细胞转染试剂和活体组织靶向试剂盒制造商AltogenBiosystems是一家生物技术公司，开发和制造用于生命科学研究、药物发现和开发的转染试剂盒。Altogen®体内转染试剂可有效地将生物分子导入靶组织。细胞转染试剂盒针对特定的癌细胞系和原代细胞进行了优化。通过先进的试剂配方和优化的转染方案实现货物分子（DNA、RNA、蛋白质）的高效传递。AltogenBiosystems利用高分子化学、分子和细胞生物学的专业知识，开发了新的体内外给药技术。转染是将外源分子导入培养细胞中，常用于研究基因功能、基因表达调控、生化定位和蛋白质生产。不幸的是，由于细胞毒性和转染效率的差异很大，并且取决于所使用的试剂、方案和细胞类型，因此没有一种单一的传递方法或转染试剂可应用于所有类型的细胞。AltogenBiosystems为120多个癌细胞系和原代细胞类型提供优化的转染试剂盒和电穿孔产品。体内转染试剂可实现组织靶向给药。Altogen的转染试剂盒包括用于体外（癌细胞系）和体内（用于动物研究的组织靶向试剂）转染的转染增强剂试剂和转染复合物冷凝器。Altogen实验室提供符合GLP的实验室合同研究服务。我们的生物CRO服务包括异种移植物的疗效、IND应用的pharm/tox研究和安全性测试、分析开发（ELISA、IC-50、qPCR）、90多个异种移植物动物模型、RNAi和基因沉默服务。Altogen的细胞培养科学家通过在28天内培育出稳定的细胞系，将选择的细胞系转化为稳定表达感兴趣的基因。